{"id":41099,"date":"2020-10-14T00:00:00","date_gmt":"2020-10-14T00:00:00","guid":{"rendered":"http:\/\/medgoo.com\/index.php\/2020\/10\/14\/covid-19-antibody-treatment-study-paused\/"},"modified":"2020-10-15T16:10:10","modified_gmt":"2020-10-15T16:10:10","slug":"covid-19-antibody-treatment-study-paused","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2020\/10\/14\/covid-19-antibody-treatment-study-paused\/","title":{"rendered":"COVID-19 Antibody Treatment Study Paused"},"content":{"rendered":"<h3>ACTIV-3 study, testing use of an antibody therapy with remdesivir, paused &#8216;out of an abundance of caution&#8217;<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>WEDNESDAY, Oct. 14, 2020 (HealthDay News) &#8212; Enrollment in a study testing an experimental antibody therapy against COVID-19 has been paused by independent monitors.<\/p>\n<p>The study, ACTIV-3, was testing the use of a single antibody with the antiviral drug remdesivir. The antibody is being developed by Eli Lilly and the Canadian company AbCellera, the <i>Associated Press<\/i> reported. The study has been paused &#8220;out of an abundance of caution,&#8221; Lilly said Tuesday, but the company did not explain what prompted the decision.<\/p>\n<p>The study is sponsored by the U.S. National Institute of Allergy and Infectious Diseases, which did not immediately comment, the <i>AP<\/i> reported.<\/p>\n<p>After falling ill with COVID-19, President Donald Trump received an experimental two-antibody cocktail from Regeneron Pharmaceuticals Inc. Regeneron and Lilly are both seeking emergency use authorization from the FDA for their COVID-19 treatments while late-stage studies continue, the <i>AP<\/i> reported.<\/p>\n<p><a href=\"https:\/\/apnews.com\/article\/virus-outbreak-donald-trump-infectious-diseases-338dafcdbf4d0c6d72812c1e8f88f6a5\" target=\"_new\" rel=\"noopener noreferrer\">More Information<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i><a href=\"https:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener noreferrer\">Health News<\/a> Copyright \u00a9 2020 <a href=\"https:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener noreferrer\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ACTIV-3 study, testing use of an antibody therapy with remdesivir, paused &#8216;out of an abundance of caution&#8217;<\/p>\n","protected":false},"author":6,"featured_media":41118,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-41099","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/41099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=41099"}],"version-history":[{"count":0,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/41099\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/41118"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=41099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=41099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=41099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}